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Abstract
Background: Protein aggregation is a hallmark of many neurodegenerative diseases and has been linked to the failure to
degrade misfolded and damaged proteins. In the cell, aberrant proteins are degraded by the ubiquitin proteasome system
that mainly targets short-lived proteins, or by the lysosomes that mostly clear long-lived and poorly soluble proteins. Both
systems are interconnected and, in some instances, autophagy can redirect proteasome substrates to the lysosomes.
Principal Findings: To better understand the interplay between these two systems, we established a neuroblastoma cell
population stably expressing the GFP-ubiquitin fusion protein. We show that inhibition of the proteasome leads to the
formation of large ubiquitin-containing inclusions accompanied by lower solubility of the ubiquitin conjugates. Strikingly,
the formation of the ubiquitin-containing aggregates does not require ectopic expression of disease-specific proteins.
Moreover, formation of these focused inclusions caused by proteasome inhibition requires the lysine 63 (K63) of ubiquitin.
We then assessed selected compounds that stimulate autophagy and found that the antihelmintic chemical niclosamide
prevents large aggregate formation induced by proteasome inhibition, while the prototypical mTORC1 inhibitor rapamycin
had no apparent effect. Niclosamide also precludes the accumulation of poly-ubiquitinated proteins and of p62 upon
proteasome inhibition. Moreover, niclosamide induces a change in lysosome distribution in the cell that, in the absence of
proteasome activity, may favor the uptake into lysosomes of ubiquitinated proteins before they form large aggregates.
Conclusions: Our results indicate that proteasome inhibition provokes the formation of large ubiquitin containing
aggregates in tissue culture cells, even in the absence of disease specific proteins. Furthermore our study suggests that the
autophagy-inducing compound niclosamide may promote the selective clearance of ubiquitinated proteins in the absence
of proteasome activity.
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Introduction
Protein homeostasis, which maintains the balance between
protein synthesis, folding and clearance, is central to cell survival.
The ubiquitin proteasome system (UPS) plays a major role in this
process by selectively degrading a large portion of short-lived
proteins [1]. For instance, under some conditions, up to 30% of
newly synthesized proteins are directly eliminated by the UPS [2].
Selective degradation by the UPS is a two-step process, in which
the substrate is first covalently attached to ubiquitin, a small 76-
amino-acid protein, and then targeted to the large multimeric
proteasome complex for proteolysis. Ubiquitin conjugation relies
on an enzymatic cascade driven by the E1 activating, E2
conjugating and E3 ligase enzymes [3]. In the human genome,
an estimated six hundred genes encode putative E3s [4]. Beside
proteolysis, ubiquitination regulates many other processes such as
endocytosis and chromatin remodelling [5]. To be efficiently
targeted to the proteasome, substrate proteins have to be attached
to a poly-ubiquitin chain, in which at least four ubiquitin
molecules are successively linked through specific lysine residues
of ubiquitin (e.g., K48 and K11) [6,7]. Prior to proteolysis,
ubiquitin itself is removed from the substrate by deubiquitinating
enzymes and recycled in the cell. The UPS degrades both key
regulatory proteins (e.g., cell cycle regulators), as well as misfolded
and damaged proteins. Failure to degrade misfolded proteins leads
to their accumulation and aggregation in the cell.
Protein aggregation is also a hallmark of a large number of age-
related neurodegenerative pathologies [8,9]. Aggregation may be
induced by the extended exposure of misfolded domains and non-
specific hydrophobic interactions that result in the formation of
amorphous structures [10]. Alternatively, aggregation can be
induced by highly ordered b–strand fibrils that form insoluble
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can cause misfolding and consequently formation of aggregates.
For example, polyglutamine repeat expansion in huntingtin
triggers the formation of insoluble amyloid-like structures in
Huntington’s disease [11]. Misfolded proteins first form small
proto-fibrils or inclusions and then are sequestered into larger
aggregates by microtubule-mediated retrograde transport [12]. A
major view is that aggregation may prevent cytotoxicity by
shielding abnormal proteins from non-specific interactions with
other proteins [13,14,15].
Impairment of the UPS has been linked to protein aggregation
[16,17]. Evidence for this view is that ubiquitin is enriched in most
symptomatic aggregates, and chemical inhibition of the protea-
some induces the formation of aggregates similar to those found in
several diseases [18,19,20,21]. Proteasome inhibition also acceler-
ates or promotes the aggregation of ectopically expressed disease-
specific proteins like huntingtin and a-synuclein [11,22].
Clearance of insoluble proteins by the lysosomes can be
mediated by macro-autophagy (hereafter called autophagy). This
pathway is characterized by the formation of double-mem-
braned vesicles that engulf cytoplasmic materials, including large
protein complexes, followed by fusion with lysosomes and
digestion by acidic hydrolases [23]. Long-lived and damaged
proteins that are poorly soluble are thought to be mainly
degraded by the lysosomes, as the proteasome cannot efficiently
process them [24]. Induction of autophagy has been shown to
reduce the aggregation of disease-specific proteins [25,26,27].
The UPS and autophagy pathways are interrelated [24] and
both critically influence events associated with aggregation
[28,29].
In the present study, we used neuroblastoma cells that stably
express GFP-ubiquitin to show that ubiquitin-containing aggre-
gates can be readily and quantitatively monitored upon chemical
inhibition of the proteasome. We found that the formation of
these ubiquitin-containing inclusions required K63 of ubiquitin,
which has been previously linked to clearance of ubiquitinated
proteins by the authophagy pathway [30,31]. Then we tested
several recently identified autophagy-modulating compounds and
found that the antihelmintic chemical niclosamide prevented the
formation of large ubiquitin-containing aggregates. Niclosamide
also affected the distribution of lysosomes in the cell. These
results suggest that niclosamide may induce the clearance of
ubiquitinated proteins that accumulate during proteasome
inhibition.
Results
Proteasome inhibition induces the formation of cellular
inclusions containing GFP-ubiquitin
We sought to monitor the formation of ubiquitin-containing
protein aggregates after inhibition of the proteasome. We used
green fluorescent protein (GFP) N-terminally fused to ubiquitin,
which produces a functional tagged ubiquitin (i.e., that can be
conjugated) [32]. Upon transient transfection in SH-SY5Y
neuronal cells, GFP-ubiquitin positive inclusions were formed
after 8 h incubation with the proteasome inhibitor MG132 (Fig.
S1A). No inclusions were detected when transiently transfected
cells were treated with DMSO or when MG132 was applied to
cells expressing GFP alone (Fig. S1A). In wild-type MG132-treated
cells, we also directly observed ubiquitin-containing aggregates by
immunofluorescence (data not shown). However, due to high
background fluorescence, it was difficult to quantify these
aggregates.
We subsequently established a cell population that stably
expresses GFP-ubiquitin and performed time-lapse microscopy
experiments to monitor the formation of the inclusions. Following
the addition of MG132, we detected a small punctum near the
nucleus in many cells after 4 h, which further increased in size
over time (Fig. 1A, Sup. Movie S1). We confirmed this observation
by analyzing fixed cells, and found that GFP-ubiquitin containing
inclusions were present in up to 80% of the cells after 12 h of
MG132 treatment (Fig. 1B), while mock treatment did not affect
GFP-ubiquitin distribution (data not shown). Large inclusions were
observed after the addition of 5 to 20 mM MG132 for 8 to 12 h.
Typically, cells contained one large inclusion with additional
smaller inclusions in few cases (Fig. S1B). Ubiquitin was also
directly detected by immunofluorescence in these inclusions (Fig.
S1C). In addition, incubation of the GFP-ubiquitin expressing cells
with epoxomicin or clasto-lactacystin b-lactone, which are specific
irreversible inhibitors of the proteasome [33,34], induced GFP-
ubiquitin enriched inclusions similar to those seen during MG132
treatment (Fig. 1C).
The MG132-induced inclusions contained GFP-ubiquitin
conjugated to low solubility polypeptides
We reasoned that the MG132-induced inclusions might be
composed of misfolded and aggregate-prone proteins that were no
longer degraded after proteasome inhibition. In order to test this
idea, we examined whether the ubiquitinated proteins that
accumulate upon proteasome inhibition displayed a lower
solubility. We first examined ubiquitinated proteins in wild-type
SH-SY5Y cells to avoid any effect of GFP on solubility. After
clearing cell lysates by centrifugation (S1), we performed a high-
speed centrifugation at 166,000 g and found that the large
majority of ubiquitinated proteins that accumulated during the
MG132 treatment were not soluble (P2; Fig. 2A). A similar
solubility profile was observed when polypeptides were conjugated
to the GFP-ubiquitin fusion (Fig. 2B). Remarkably, while the
majority of unconjugated GFP-ubiquitin remained in the soluble
fraction, the low solubility fraction was mainly enriched with
conjugated GFP-ubiquitin. This data strongly suggests that the
inclusions observed in MG132-treated cells were composed of
GFP-ubiquitin conjugated to low solubility proteins.
We next sought to determine whether ubiquitinated proteins
were persistent in the MG132-induced inclusions. It was
previously shown that aggregating proteins have low exchange
rates with their cytoplasmic pools [35,36]. In contrast, proteins
involved in the aggregation process display a more rapid
dynamics and shuttle from the aggregates to the cytosol. For
instance, the pool of hsp70 in huntingtin aggregates is replaced by
cytosolic hsp70 within less then one minute [36]. To assess the
diffusion or exchange rates of proteins conjugated to GFP-
ubiquitin in the MG132-induced inclusions, we performed
fluorescence recovery after photo-bleaching (FRAP). While the
cytosolic GFP-ubiquitin signal was rapidly recovered in a photo-
bleached area, the loss of fluorescence lasted over one minute in
the ubiquitin-containing inclusions after FRAP (Fig. 2C). This
persistent loss suggested that ubiquitinated proteins were stable in
the aggregates and not rapidly exchanged with other ubiquiti-
nated cytosolic proteins. We conclude that the GFP-ubiquitin
containing inclusions caused by proteasome inhibition were likely
composed of non-degraded and aggregation-prone proteins
conjugated to GFP-ubiquitin. We hereafter refer to these
structures as aggregates. Notably, these ubiquitin-containing
aggregates were formed in the absence of ectopic expression of
disease-related proteins prone to aggregation.
Niclosamide and Aggregation
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14410Formation of ubiquitin containing aggregates requires
K63 conjugation
It waspreviously suggested that formationofaggregatesinseveral
models requires formation of poly-ubiquitin chains linked by lysine
63 (K63) [30,31,37,38]. To determine whether specific types of
ubiquitin chains are associated with the formation of ubiquitin-
containing aggregates caused by proteasome inhibition, we
transfected different GFP-ubiquitin mutants in SH-SY5Y cells.
Formation of aggregates was similar between wild-type ubiquitin
andtheK48R-ubiquitinmutant(inwhichthe K48wasmutatedtoa
arginine residue; Fig. 2D). In contrast, the K63R-ubiquitin mutant
was unable to form focused aggregates after proteasome inhibition,
and instead, led to the accumulation of punctuate-like structures in
the periphery of the cytoplasm (Fig. 2D; see insets). This data
suggests that conjugation of K63 is required for the formation of
large and focused ubiquitin containing aggregates. To further test
the requirement of K63 linkage in the aggregation of proteasome
substrates, we transfected additional ubiquitin mutants tagged to
HA (hemagglutinin) in SH-SY5Y cells that stably expressed GFP-
ubiquitin. We found that the K63-only ubiquitin mutant (in which
allKexceptK63aremutated to R)formeda normalaggregateafter
MG132 treatment (Fig. 2E). This data indicates that K63 is
sufficient for the formation of induced aggregates. Remarkably, the
K48-only ubiquitin mutant was unable to form aggregates, in
agreement with a requirement for K63 (Fig. 2E). All together, these
results indicate that ubiquitinated proteins that localize in the
aggregates after proteasome inhibition are conjugated to poly-
ubiquitin chains principally linked by K63.
Formation of large ubiquitin-containing aggregates
requires an intact microtubule network
The microtubule network is required for the formation of
large aggresomes, as smaller aggregates or proto-fibrils are
retrogradely transported by dynein motor proteins to the
centrosome [39,40,41]. We found that the MG132-induced
inclusions enriched with GFP-ubiquitin co-localized with c-
tubulin, which primarily localizes to the centrosome (Fig. S2A).
Moreover, the addition of the microtubule-depolarizing agent
nocodazole together with MG132 induced a distinct pattern with
multiple small GFP-ubiquitin puncta spread throughout the
cytoplasm (Fig. 3A, S2B). Similar results were obtained when
nocodazole was added together with clasto-lactacystin b-lactone
(Fig. S2B). To better quantify this phenomenon, we analyzed the
data using an automated high-content fluorescence imager.
Individual cells were detected after applying a mask around
Hoechst-stained nuclei, and induced GFP-ubiquitin aggregates
were identified using a GFP-signal intensity threshold (Fig. 3B;
see purple puncta in middle inset). After the addition of MG132,
the induced aggregates were detected as a strong increase in
signal intensity (Fig. 3C). The addition of nocodazole induced a
major reduction in both aggregate average intensity signal (2.6
fold, Fig. 3C) and aggregate average size (3.8 fold, Fig. 3D). This
decrease was caused by the reduction of the GFP-signal intensity
below the threshold in most inclusions, and confirmed that
depolymerisation of microtubules prevented the formation of
large aggregates in the cell. Thus, the large GFP-ubiquitin
inclusions induced by proteasome inhibition were localized next
Figure 1. Ubiquitin-containing aggregates caused by proteasome inhibition. (A) Formation of aggregates (arrowheads) induced with
20 mM MG132 was monitored by live-imaging a SH-SY5Y cell population that stably expresses GFP-ubiquitin. Two representative cells (indicated with
one and two asterisks) are shown at different times. Scale bar represents 10 mm. (B) Percentage of methanol-fixed GFP-ubiquitin SH-SY5Y cells
containing at least one GFP-ubiquitin inclusion (defined by a four fold increase of GFP signal intensity) after the addition of 20 mM MG132 for the
indicated times. Average of three experiments with standard errors are shown (n=200). (C) Representative methanol-fixed GFP-ubiquitin cells treated
with 10 mM MG132, 1 mM epoxomycin or 2 mM clasto-lactacystin b-lactone for 12 h. Scale bar represents 10 mm.
doi:10.1371/journal.pone.0014410.g001
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network for their formation. Overall, these data indicate that the
aggregates are similar to previously observed aggresome
structures [42].
Niclosamide inhibits the formation of the large ubiquitin-
containing inclusions induced after proteasome
inhibition
Autophagy has been shown to participate in clearing cellular
aggregates formed by disease-specific proteins [25,26,27]. We
recently identified niclosamide, perhexiline, and rottlerin as
compounds capable of rapidly inducing autophagy [43]. We
therefore sought to determine whether they can also alter the
formation of the ubiquitin-containing aggregates induced by
proteasome inhibition. The chemicals were added for 8 h in
combination with MG132 to cells stably expressing GFP-
ubiquitin, and large aggregates were quantified using the
automated high-content imager. Niclosamide, a salicylanilide
antihelmintic drug [44,45,46] reduced, in a concentration-
dependent manner, the induction of large aggregates by MG132
(Fig. 4A, Fig. S4A, B). Treatment with niclosamide led instead to
the formation of more but smaller GFP-ubiquitin inclusions
(Fig. 4B; Fig. S3C). The two other compounds did not significantly
reduce large aggregate accumulation (Fig. 4A). Interestingly,
niclosamide alone induced a small increase in signal intensity
(Fig. 4A; see below). Maximal response with 5 mM MG132 was
reached at 20 mM niclosamide (IC50 of ,5 mM). Moreover,
niclosamide reduced the induction of ubiquitin-containing aggre-
gates by epoxomicin (Fig. 4C), arguing against a specific
interaction with MG132 itself. Likewise, niclosamide also affected
the aggregate size when it was added to cells pre-treated for 4 h
with the irreversible proteasome inhibitor epoxomicin. Large
ubiquitin-containing aggregates were observed if cells were treated
for 4 h with DMSO after washing away epoxomicin, but not when
cells were treated with niclosamide (Fig. S3D). In addition, two
analogues closely related to niclosamide, which are unable to
activate autophagy (Balgi A.D. et al., manuscript in preparation),
did not affect the formation of the ubiquitin-containing inclusions
(Fig. 4D). We deduce that niclosamide is able to specifically alter
the formation of the large ubiquitin-containing aggregates caused
by proteasome inhibition.
Niclosamide prevents the accumulation of ubiquitinated
proteins after proteasome inhibition and causes a
redistribution of the lysosomes in the cell
The reduced induction of large ubiquitin-containing aggregates
by MG132 in niclosamide-treated cells could be explained by a
diminution in the accumulation of ubiquitinated proteins. To test
this idea, we first examined the overall ubiquitination levels in SH-
SY5Y cells. While treatment with MG132 alone led to an
accumulation of ubiquitinated species, addition of niclosamide
(with MG132) largely prevented this increase (Fig. 5A). We
observed a similar decrease in ubiquitination when we monitored
the levels of GFP-ubiquitin conjugation after adding niclosamide
and MG132 in cells stably expressing the fusion protein (Fig. S4A).
Concurrently, there was no significant increase of ubiquitinated
species in the pellets obtained after centrifugation of the cell lysates
(data not shown), indicating that the reduction was not due to a
change of solubility of the ubiquitin conjugates. One possibility is
that niclosamide induces the clearance of ubiquitinated proteins
that accumulate after proteasome inhibition. Alternatively, it could
prevent the ubiquitination of proteasome substrates.
We next examined whether niclosamide alone could alter
ubiquitination levels in cell with normal proteasome activity (i.e.,
without MG132). While no major change of poly-ubiquitination
levels was consistently observed (a minor decrease was observed in
some cases), a lower molecular-weight signal (,22 KDa) that
presumably corresponds to ubiquitinated H2A histone protein
disappeared in niclosamide-treated cells (Fig. 5B). Ubiquitination
is a dynamic process, in which ubiquitinated substrates are in
equilibrium between ubiquitination and de-ubiqutination. It has
been shown that a reduction in the amount of free mono-ubiquitin
in the cell (e.g., due to heat shock stress) causes a decrease in H2A
ubiquitination [32,47]. It was suggested that the enzymes involved
in H2A ubiquitination could not compete with other E2/E3s when
the amount of free ubiquitin was reduced in the cell, leading to a
gradual de-ubiquitination of H2A. We observed that levels of H2A
in the cell were not affected by niclosamide (Fig. S4B), suggesting
that H2A was likely de-ubiquitinated in the presence of
niclosamide. These results indicate that niclosamide may reduce
the amount of free ubiquitin in the cell, which would then lead to
the de-ubiquitination of H2A.
Niclosamide alone induced a concentration-dependant increase
in signal intensity of the GFP-ubiquitin containing aggregates
(Fig. 4A). We observed, by microscopy, that a small GFP-ubiquitin
positive inclusion was formed next to the nucleus in cells treated
with niclosamide alone (Fig. 5C, Fig. S4C; see arrowheads). These
inclusions were significantly smaller than the MG312-induced
aggregates (see also Fig. S3C). Intriguingly, small puncta were also
found throughout the cell, which typically led to a specific increase
of GFP-ubiquitin signal intensity (Fig. 5C; see signal quantification
of the cross section). For comparison, the GFP-ubiquitin signal
remained diffuse in mock-treated cells. These data indicate that
niclosamide affects ubiquitin distribution in the cell. Interestingly,
niclosamide treatment also induced a change of lysosome
distribution in the cell (Fig. 5D; Fig. S4D). In mock-treated cells,
lysosomes are primarily found in one region of the cell next to the
nucleus. It has been previously shown that lysosomes localize next
to the centrosome in a microtubule-dependent manner [48,49].
Remarkably, lysosomes were redistributed throughout the cell
Figure 2. Low solubility proteasome substrates aggregate in a ubiquitin K63-dependent manner. (A) Schematic diagram of the cell
fractionation based on protein solubility (left). Wild-type SH-SY5Y cells were incubated with 20 mM MG132 or DMSO for 12 h prior to lysis with 0.5%
NP40 buffer. Total cell lysates (T), detergent-soluble (S1) and insoluble (P1) fractions, and high-speed soluble (S2) and insoluble (P2) fractions were
subjected to 4–20% SDS-PAGE and immunoblotting with an anti-ubiquitin antibody. (B) GFP-ubiquitin SH-SY5Y cells were treated with 20 mM MG132
for 12 h and analyzed as in A. (C) GFP-ubiquitin SHY5Y cells treated with 10 mM MG132 for 12 hours were imaged live by fluorescence confocal
microscopy before and after photobleaching of on area in the cytoplasm (top) or in the inclusion (bottom). Typical images of SH-Y5Y GFP-ubiquitin
cells before, immediately after and 30 and 60 seconds after photobleaching are shown. Color-coded pixel fluorescence intensities are shown in the
right panel. Fluorescence intensities relative to the pre-treated area were reported for each time point (right). Data represent the mean 6 SEM (n=7
cytoplasm; n=4 inclusions) of the normalized bleached region. (D) SH-SY5Y cells transiently transfected with the indicated GFP-ubiquitin constructs
for 24 h prior to treatment with 5 mM MG132 for 8 h and PFA fixation with Hoechst. Two insets showing cells transfected with K63R-ubiquitin are
shown to the right. (E) GFP-ubiquitin SH-SY5Y cells transiently transfected with the indicated HA-ubiquitin constructs for 24 h prior to treatment with
5 mM MG132 for 12 h and methanol fixation. Immuno-fluorescence was performed using mouse anti-HA and anti-mouse Alexa568 (Invitrogen)
antibodies. All scale bars represent 10 mm.
doi:10.1371/journal.pone.0014410.g002
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larger in niclosamide-treated cells. This data suggests that
niclosamide causes a change in lysosome localization and possibly
in their activity.
Inhibition of mTORC1 pathway by rapamycin does not
mimic the effect of niclosamide on ubiquitination
Niclosamide has been shown to inhibit mTORC1, one of the
two complexes that share the mTOR kinase [43]. We next sought
to determine whether rapamycin, the prototypical mTORC1
inhibitor, could mimic the effect of niclosamide, as it was shown to
induce autophagy [50]. Treatment with rapamycin alone did not
induce any significant change in GFP-ubiquitin distribution in the
cell (Fig. 6A) or in lysosome localization (Fig. S5A). Furthermore,
in contrast to niclosamide, rapamycin did not prevent the
accumulation of ubiquitinated proteins after the addition of
MG132 (Fig. 6B). Levels of phosphorylated SK6 dropped in SH-
SY5Y cells treated with rapamycin, confirming it was effectively
inhibiting mTORC1 (Fig. 6B). Finally, we verified that rapamycin
did not alter the formation of GFP-ubiquitin containing aggregates
Figure 3. Formation of induced GFP-ubiquitin aggregates is impaired by nocodazole. (A) GFP-ubiquitin SH-SY5Y cells were treated with
5 mM MG132 together with 2 mM nocodazole for 8 h prior to methanol fixation and Hoechst staining (blue). Scale bar represents 10 mm. (B, C and D)
GFP-ubiquitin SH-SY5Y cells were treated as indicated with 5 mM MG132 and 5 mM nocodazole for 8 h prior to fixation and quantification with the
automated high-content fluorescence imager. Representative images are shown (B). Insets show MG132-treated cells detected with a Hoechst mask
(blue contours) and their associated aggregates (purple; arrowheads), as well as an object rejected (red contour) because of its strong signal intensity.
Scale bar represents 100 mm. Signal intensity (C) and area in mm
2 (D) of the GFP-ubiquitin aggregates. Results are the mean of three independent
wells with standard deviations. The numbers of analyzed cells to calculate the average intensity (or area) in each well are indicated below the
histogram.
doi:10.1371/journal.pone.0014410.g003
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that treatment of rapamycin alone is not sufficient to mimic the
effects of niclosamide. Hence, mTORC1 inhibition by rapamycin
does not induce the selective clearance of ubiquitinated proteins,
and cannot prevent the formation of ubiquitin-containing
aggregates caused by proteasome inhibition.
Niclosamide affects p62 levels when the proteasome is
inhibited
p62/Sequestosome 1 is a scaffold protein that tethers ubiqui-
tinated proteins to autophagosomes, promoting their uptake to the
lysosomes [28]. p62 is degraded in this process and up-regulation
of autophagy causes a reduction of p62 levels [51]. In SH-SY5Y
cells, both rapamycin and niclosamide induced a decrease of p62
levels, consistent with enhanced degradation by autophagy (Fig.
S5B). Surprisingly, rapamycin did not cause any significant change
of p62 levels when the proteasome was inhibited (Fig. 6D). It was
previously shown that both mRNA and protein levels of p62
increase upon proteasome inhibition [52]. One possibility is that
p62, which interacts with ubiquitinated proteins, becomes trapped
in large aggregate structures caused by proteasome inhibition. As
shown by the GFP-ubiquitin induced aggregate assay, these
structures are not efficiently cleared after the induction of
autophagy with rapamycin (Fig. 6C); hence, explaining why p62
levels remained high in the cells. In contrast, niclosamide, which
prevents the formation of large ubiquitin-containing aggregates,
caused a strong reduction of p62 during treatment with MG132
(Fig. 6D). To exclude that the decrease of p62 levels was due to the
inhibition of p62 expression, we added niclosamide to cells after a
pre-treatment of 4 h with the proteasome inhibitor epoxomicin in
SH-SY5Y cells. Under these conditions, p62 levels continued to
increase 2 and 4 h after the removal of epoxomicin, as
proteasomes remained inactive in these cells (Fig. 6E). In contrast,
when niclosamide was added after the pre-treatment, p62 levels
decreased at 4 h (Fig. 6E). These results indicate that, in absence
of proteasome activity, niclosamide induces the degradation of
p62, most likely while it is associated with ubiquitinated proteins.
Selective autophagy pathways can specifically target to the
lysosomessubsets of proteins or organelleslikethe ribosomes [53] or
damaged mitochondria [54,55,56]. We examined whether niclosa-
mide could induce the clearance of other specific subsets of proteins
in addition to ubiquitin. We found that niclosamide did not induce
any significant reduction of Rpl5 ribosome protein (Fig. S5C) or
Tom20 mitochondria protein (Fig. S5D). These results indicate that
niclosamide does not cause the clearance of other large complexes/
organelles like ribosomes or mitochondria. We infer that niclosa-
mideselectively prevents the accumulationof ubiquitinated proteins
in the cell by possibly targeting them for degradation by the
lysosomes (or via another proteasome-independent pathway),
without targeting other large protein complexes.
Discussion
We show here that inhibition of the proteasome induces the
accumulation of poorly soluble ubiquitinated proteins associated
Figure 4. Niclosamide affects the formation of the ubiquitin-
enriched aggregates caused by proteasome inhibition in SH-
SY5Y cells. (A) Signal intensities of the aggregates in SH-SY5Y cells
stably expressing GFP-ubiquitin treated for 8 h with different autoph-
agy inducers. The following concentrations were used: niclosamide (1, 3
and 10 mM), rottlerin (0.1, 1, 3 mM) and perhexiline (1, 3, 10 mM) alone
(light grey), and together with 5 mM MG132 (dark grey). Mean
intensities (with standard deviations) were measured in three indepen-
dent wells for each condition using the automated high-content
fluorescence imager. The p values for the designated samples
calculated by Student’s t-test were 0.03 and 0.0014, respectively. (B)
Representative images of cells incubated as indicated with 5 mM MG132
and 10 mM niclosamide for 8 h prior to PFA fixation. Scale bar
represents 10 mm. Preceding time points are shown in Fig. S3C. (C,
D) Same as in A, using 1 mM epoxomycin, 5 mM MG132, 10 mM
niclosamide or 10 mM of niclosamide analogues #1 and #2. The p
values for the designated samples calculated by Student’s t-test were
,0.0001 (C) and 0.006 (D).
doi:10.1371/journal.pone.0014410.g004
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SY5Y cells. In addition, GFP-ubiquitin in aggregates is not rapidly
exchanged, indicating that the aggregating polypeptides conjugat-
ed to ubiquitin are steady in these structures. Notably, the
formation of the ubiquitin-containing aggregates does not require
the presence of any disease-specific proteins. A large portion of
proteasome substrates is composed of short-lived misfolded or
damaged proteins, which are mainly derived from abundant
cellular proteins [2,57]. Therefore, these aggregates are likely
composed of a wide array of misfolded proteins accumulating
during proteasome inhibition. In agreement with this, we found by
mass spectrometry that chaperone proteins, which typically bind
to misfolded proteins, are strongly enriched in these aggregates
(I.B.W., M.B., J.M.W., T.M., manuscript submitted).
A decrease in proteasome activity has been observed during the
formation of amyloid-like aggregates [58,59]. It has been proposed
that the ubiquitin-enriched inclusions may trap and stall the
proteasome with irreversibly misfolded proteins [17]. Our results
suggest that inhibition of the proteasome triggered by insoluble
proteins in symptomatic cells would cause the accumulation of
additional aggregation-prone proteins (i.e., common proteasome
substrates) and most likely increase the stress in these cells.
Remarkably, K63 of ubiquitin is required and is sufficient for the
formation of these induced ubiquitin-containing aggregates.
Proteasome inhibition has been shown to rapidly induce the
accumulation of mostly K48-linked ubiquitin chains [6]. One
possibility is that poly-ubiquitin chains are further ubiquitinated
via K63 after prolonged proteasome inhibition to promote
aggregate formation. Consistent with this idea the laboratory of
J. Peng recently showed that K63-linkages accumulate in the cell
after prolonged inhibition of the proteasome, but not as rapidly as
K48 linkages [60]. There may be factors in the cell that might
favour the ‘‘remodelling’’ of ubiquitin chains after prolonged
proteasome inhibition to foster the aggregation of non-degraded
proteasome substrates.
The autophagy-inducing compound niclosamide precludes the
formation of the large ubiquitin-containing aggregates generated
during proteasome inhibition. In the presence of niclosamide,
Figure 5. Niclosamide affects ubiquitination levels and lysosome distribution in the cell. (A) SH-SY5Y cells were treated as indicated with
5 mM MG132 and 10 mM niclosamide for 8 h prior to lysis in RIPA buffer. Equal amounts of proteins were separated by 4–20% SDS-PAGE followed by
immunoblotting with ubiquitin and PSTAIR antibodies. (B) Same as A, with cells treated with 10 mM niclosamide or DMSO (0.2%) for 8 h. (C)
Representative GFP-ubiquitin SH-SY5Y cells treated with 10 mM niclosamide or DMSO for 8 h, prior to PFA fixation and Hoechst staining (shown in the
insets). GFP signal based on the camera pixel intensity (vertical axis) for the highlighted 5 mm cross-sections (white bars) is shown on the right side.
(D) Representative GFP-ubiquitin SH-SY5Y cells treated with 10 mM niclosamide or DMSO for 8 h, as well as with lysotracker for 1 h, prior to imaging
of live cells. Scale bar represents 10 mm.
doi:10.1371/journal.pone.0014410.g005
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decrease of p62 during proteasome inhibition. In addition,
niclosamide causes a redistribution of the lysosomes throughout
the cell. It may therefore induce the clearance of ubiquitinated
proteins and associated proteins by the lysosomes when the
proteasome is inhibited. Surprisingly, we found that the induction
of autophagy with the prototypical mTORC1 inhibitor rapamycin
affected neither the formation of large GFP-ubiquitin containing
aggregates, nor did it prevent the accumulation of poly-
ubiquitinated conjugates caused by MG132. Rottlerin and
perhexiline, which also induce autophagy by inhibiting mTORC1,
similarly failed to alter the large aggregates induced by MG132.
These results may indicate that up-regulation of autophagy by
mTORC1 inhibition is not sufficient to induce a rapid clearance of
large ubiquitin-containing aggregates. On the other hand, it has
recently been discovered that rapamycin does not inhibit all
functions of mTORC1 and that it does not strongly induce
autophagosomes [61]. It is conceivable that mTORC1 is involved
in this response and that niclosamide targets an mTORC1
substrate not inhibited by rapamycin.
Niclosamide induces a change of lysosome localization that may
facilitate the uptake of ubiquitinated proteins when the protea-
some is inhibited. In untreated cells, a majority of the soluble
misfolded proteins is targeted for degradation by the ubiquitin
proteasome system, while insoluble proteins are normally cleared
by a cluster of lysosomes next to the centrosome [49](Fig S6A).
Niclosamide causes a change of lysosome localization throughout
the cell. It also causes the formation of small ubiquitin-containing
inclusions next to the nucleus. Because lysosomes are redistributed
throughout the cell, clearance of insoluble proteins next to the
centrosome may be reduced, causing formation of small inclusions.
When the proteasome is inhibited, ubiquitinated misfolded
proteins accumulate in the cell and form large aggregate structures
next to the centrosome (Fig. S6B). A small portion of ubiquitinated
proteins is likely degraded by the lysosomes. For instance, we
found that the addition of the lysosomal inhibitor chloroquine
causes a slight increase in the aggregate size (data not shown).
Intriguingly, the lysosomes are not able to clear the large
ubiquitin-containing aggregates, even when autophagy is up-
regulated with rapamycin. In contrast, the autophagy-inducing
compound niclosamide blocks the accumulation of ubiquitinated
proteins during proteasome inhibition. While still speculative, it is
possible that this phenomenon is mediated by the degradation of
ubiquitinated proteins by the lysosomes. An uptake of the
ubiquitinated proteins could be favoured by the redistribution of
the lysosomes before the formation of large aggregate structures
Figure 6. Niclosamide but not rapamycin affects the formation
of large ubiquitin-containing aggregates and p62 levels. (A)A
representative GFP-ubiquitin SH-SY5Y cell treated with 20 nM rapamy-
cin for 8 h, prior to PFA fixation and Hoechst staining. GFP signal
intensity (vertical axis) for the indicated 5 mm cross-section (white bar) is
shown on the right side. (B) SH-SY5Y cells were treated as indicated
(5 mM MG132, 10 mM niclosamide, 20 and 100 nM rapamycin) for 8 h,
prior to lysis in RIPA buffer. Equal amounts of proteins were separated
by 4–20% SDS-PAGE followed by immunoblotting with ubiquitin, SK6
and anti-a-tubulin antibodies. (C) Signal intensities of the GFP-ubiquitin
aggregates were measured in three independent wells for a each
condition using the automated high-content fluorescence imager. Cells
were treated with rapamycin (10, 30, 100 nM) alone (light grey), and
together with 5 mM MG132 (dark grey) for 8 h. (D) Same as B but with
anti-p62 and anti-a-tubulin antibodies. (E). SH-SY5Y cells were pre-
treated with 1 mM epoxomicin for 4 h, prior to cell wash. Mock-DMSO
or niclosamide treated cells were then further incubated for the
indicated times and processed as in D.
doi:10.1371/journal.pone.0014410.g006
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lysosome redistribution) may improve the efficacy of aggregate
clearance.
Materials and Methods
Plasmids
The first ubiquitin sequence of the scUBI4 gene was ampli-
fied with 59CTCAABCTTCTATGCAGATTTTCGTCAAGA-
CT and 59GAGCTCGAGACCACCTCTTAGCCTTAGCAC
primers, and subcloned into pEGFP-C1 (Clonetech) using Hind
III and Xho I restriction sites; the K48R and K63R were similarly
amplified and subcloned into pEGFP-C1 using GST-ubiquitin
cDNAs kindly provided by M. Petroski (Burnham Institute for
Medical Research); the HA-ubiquitin constructs are described
elsewhere [62].
Cell culture
SH-SY5Y (ATCC, CRL-2266) cells were cultured in DMEM/
F12 mixture (1:1) supplemented with 10% FBS and 1% Pen/Strep
(Invitrogen) at 37uCi n5 %C O 2. Calcium phosphate transfection
was performed with cells at 30–60% confluency. Cells stably
expressing GFP-ubiquitin fusion protein were selected with
0.5 mg/ml G418. At 70–90% cells confluency and 24 h after
seeding on culture dishes or on HCl-treated coverslips, MG132
(DiscoveryScientific; 25 mg/ml in DMSO), epoxomicin (Biomol),
clasto-lactacystin b-lactone (Biomol), nocodazole (Santa Cruz) and
other indicated chemicals (Sigma) were added (with fresh media) at
the indicated concentrations and for the indicated time. Lyso-
tracker (Molecular Probes) was added 1 h prior to imaging.
Microscopy, live cell imaging and FRAP
For fluorescence microscopy, cells were either fixed in 220uC
methanol for 6 min or in 3% paraformaldehyde (PFA) for 15 min.
All cells were incubated with Hoechst 33342 (Molecular Probes)
and mounted on glass slides topped with ProLong Gold
(Invitrogen). All images were acquired with an AxioObserverZ1
equipped with a Colibri-LED-system (365/470/590 nm) and an
AxioCam HRm, and with either an 63x oil Plan-Apochromat
(fixed cells) or an 40x oil EC Plan-Neofluar objective (live cells)
prior to processing with the AxioVision rel 4.7 software (Zeiss).
Wavelet extended focus function was used with all in-focused Z-
stacked images for each picture. Live cell imaging was performed
using the live cell system Chamlide IC (Life Cell Instrument). Cells
were seeded on coverslips at 50% confluency, 24 h prior to the
assembly of the 35 mm dish-type magnetic chamber and the
addition of 1 ml of fresh media with MG132, which were then
placed into the pre-warmed (37uC) microscope chamber supplied
with 5% CO2. One hour after MG132 addition, 24 Z-stack images
were taken (every 0.5 mm; each 25 ms) with the 470 nm LED
module (set at 25% light intensity) every 15 minutes for 11 h. For
FRAP analysis, fluorescence was bleached at a 488-nm (GFP)
square region, and scanned images were collected at the indicated
times on a Nikon SP1 confocal microscope. Fluorescence was
quantified using Nikon EZview software. The remaining fluores-
cence in the bleached region after bleach was substracted from all
data points. The ratio of the mean fluorescence in the bleached
region over the pre-bleached value is shown for each data point.
Analysis with automated fluorescence imager
20,000 cells/well were seeded on 96-well microtiter plates
(Perkin-Elmer) 24 h prior to chemical treatment. Fresh medium
supplemented with the indicated compounds was added for 8 h
and cells were fixed with PFA prior to staining with 500 ng/ml
33342 Hoechst. Fixed cells were washed and kept in PBS
containing 1 mM MgCl2 and 0.1 mM CaCl2 during the analysis
with the Cellomics Arrayscan VTI Reader (Thermo Fisher) using
a 20x objective. A cytoplasmic mask was generated using the
compartment analysis algorithm and aggregates were detected
using the ‘‘circ spot average intensity’’ or ‘‘circ spot average size’’
with a band pass fixed at 351 pixel intensity units for GFP signal
(XF-100 filter). Objects with less than 10 average pixel intensity
units (GFP) were automatically excluded from the analysis. 10
different 350 mm
2 fields per well were analyzed, which typically
resulted in .2000 analyzed cells/well. Means and standard
deviations were calculated from data generated in three indepen-
dent wells.
Protein extracts
Cells harvested by trypsinization were lysed in 0.5% NP40,
150 mM NaCl, 25 mM Hepes pH 7.4, 1 mM PMSF, 1x complete
protease inhibitors or RIPA buffer. All cell extracts were cleared at
16,000 g in a microfuge at 4uC for 10 minutes. High-speed
centrifugation was performed at 166,000 g in a TLS-55 (Beckman)
for 10 minutes. Normalization was performed after Bradford
assays (Bio-Rad) prior to protein separation by 4–20% SDS-PAGE
(Nusep inc). Immuno-staining were performed with P4G7 anti-
ubiquitin (1:250–1000, Santa Cruz), PSTAIR (1:1000, Santa
Cruz), (E-19)-R anti-a-tubulin (1:1000, SantaCruz), C18 anti-S6K
(1:5000, Santa Cruz) and anti-p62 (1:250, Santa Cruz) antibodies,
followed by incubation with a secondary HRP-conjugated
antibody (1:3000, Bio-Rad).
Supporting Information
Figure S1 Ubiquitin-containing aggregates caused by protea-
some inhibition. (A) GFP-ubiquitin forms aggregates after
proteasome inhibition with MG132. Transient calcium phosphate
transfection was performed with SH-SY5Y cells seeded at 30–50%
confluency with either GFP or GFP-ubiquitin cDNAs for 24 h
prior to treatment with 5 mM MG132 or an according amount of
DMSO for an additional 8 h. Cells were fixed with PFA and
stained with Hoechst. Scale bar indicates 10 mm. (B) Histograms
represent the averaged proportions of GFP-ubiquitin SH-SY5Y
cells with none, one large GFP-ubiquitin inclusion alone, or one
large inclusion with smaller inclusions, after treatment with 20 mM
MG312 for 12 h, in two independent experiments (n=100). (C)
Immunofluorescence was performed on methanol fixed GFP-
ubiquitin SH-SY5Y cells after the addition of 10 mM MG312 for
12 h. The FK2 (1:250, Boston Biochem) antibody, which
recognizes both mono and poly-ubiquitin, was employed in
combination with Alexa 568 anti-mouse antibody (1:1000,
Invitrogen) and Hoechst staining. Scale bar represents 10 mm.
Found at: doi:10.1371/journal.pone.0014410.s001 (1.86 MB TIF)
Figure S2 Ubiquitin-containing aggregates caused by protea-
some inhibition localize at the centrosome. (A) GFP-ubiquitin
aggregates localize at the centrosome. Immunofluorescence was
performed on methanol fixed GFP-ubiquitin SH-SY5Y cells after
treatment with 20 mM MG312 for 10 h. The anti c-tubulin (1:500,
Sigma-Aldrich) antibody was employed in combination with Alexa
568 anti-mouse antibody and Hoechst staining. Scale bar
represents 10 mm. (B) Nocodazole prevents the formation of large
GFP-ubiquitin aggregates. Percentages of cells (n=100) with at
least one large inclusion (diameter .1.25 mm) were calculated in
GFP-ubiquitin SH-SY5Y cells treated as indicated with 5 mM
MG312, 2 mM nocodazole, and 1 mM clasto-lactacystin b-lactone
for 8 h prior to methanol fixation and imaging.
Found at: doi:10.1371/journal.pone.0014410.s002 (1.70 MB TIF)
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enriched aggregates caused by proteasome inhibition. (A) Signal
intensities of the GFP-ubiquitin aggregates (with standard
deviations) in cells treated for 8 h with the indicated concentra-
tions of niclosamide alone (light grey) or together with 5 mM
MG132 (dark grey) were measured in three independent wells
using the automated high-content fluorescence imager. (B) Fold
decreases (with standard errors) of the aggregate signal intensity
calculated using three series of niclosamide concentrations (same
data as in A). (C) Niclosamide prevents the formation of the large
ubiquitin-containing aggregates in presence of MG132. Repre-
sentative images of cells incubated as indicated with 5 mM MG132
and 10 mM niclosamide prior to PFA fixation. Hoechst staining of
the cells is shown in the insets. Scale bar represents 10 mm. The
cells at the 8 h time point are the same as in Fig. 3B. (D)
Niclosamide prevents the formation of the large ubiquitin-
containing aggregates in cells pre-treated with epoxomicin. SH-
SY5Y cells stably expressing GFP-ubiquitin were treated for 4 h
with 1 mM epoxomicin before changing the media and adding
DMSO or 10 mM niclosamide for another 4 h. Cells were fixed
with cold methanol. Hoechst staining of the cells is shown in the
insets. Scale bar represents 10 mm.
Found at: doi:10.1371/journal.pone.0014410.s003 (1.86 MB TIF)
Figure S4 Niclosamide affects ubiquitination levels and lysosome
distribution in the cell. (A) SH-SY5Y cells stably expressing GFP-
ubiquitin were treated as indicated for 8 h. Equal amounts of
proteins were separated by 4–20% SDS-PAGE followed by
immunoblotting with anti-GFP (Roche) and anti a-tubulin (Sigma).
(B) Niclosamide does not alter levels of histone H2A. SH-SY5Y cells
were treated as indicated for 8 h and lysed in RIPA buffer. Equal
amounts of proteins were separated by 4–20%SDS-PAGE followed
by immunoblotting with histone H2A and PSTAIR antibodies. (C)
Niclosamide causes a change of GFP-ubiquitin distribution in the
cell. Representative images of cells incubated as indicated with
DMSO or 10 mM niclosamide prior to PFA fixation. Hoechst
staining of the cells is shown in the insets. Scale bar represents
10 mm. The cells at the 8 h time point were also shown in Fig. 4C.
(D) Niclosamide causes a change of the lysosome distribution in the
cell. Additional representative images (as shown in Fig. 4D) of cells
incubated as indicated with DMSO or 10 mM niclosamide for 8 h.
Lysotracker was added one hour prior to imaging of live cells
performed in the pre-warmed Chamlide IC microscope chamber
supplied with 5% CO2. Scale bar represents 10 mm.
Found at: doi:10.1371/journal.pone.0014410.s004 (2.96 MB TIF)
Figure S5 Niclosamide but not rapamycin affects lysosome
distribution and p62 levels during proteasome inhibition. (A)
Representative GFP-ubiquitin SH-SY5Y cells treated with 20 nM
rapamycin for 8 h, as well as with lysotracker for 1 h, prior to
imaging of live cells. Scale bar represents 10 mm. (B–D) SH-SY5Y
cells were treated as indicated for 8 h and lysed in RIPA buffer.
Equal amounts of proteins were separated by 4–20% SDS-PAGE
followed by immunoblotting with anti-p62 and PSTAIR antibod-
ies (B), with anti-Rpl5 (molecular probes) and PSTAIR antibodies
(C) and anti-Tom20 (1:500, Santa Cruz) and alpha-tubulin
antibodies (D; the same membrane as in Fig. 5B was used).
Found at: doi:10.1371/journal.pone.0014410.s005 (2.08 MB TIF)
Figure S6 Schematic representations of the possible effects of
niclosamide in the cell. (A) In unstressed cells, the majority of poly-
ubiquitinated proteins are degraded by the proteasome. A small
fraction of insoluble ubiquitinated proteins is targeted to the
lysosomes, which are specifically enriched in one region of the cell
(next to the centrosome). (B) The addition of the MG132
proteasome inhibitor leads to the accumulation of a large amount
of non-degraded proteins that form a large aggregate. While a
small portion of the proteins is degraded by the lysosomes, they
cannot effectively clear all these proteins (even when autophagy is
activated with rapamycin). (C) When niclosamide is added with
MG132, the redistribution of the lysosomes throughout the cell
may possibly facilitate the uptake and degradation of non-
degraded ubiquitinated proteins prior to their accumulation in a
large aggregate. This would lead to the formation of a small
aggregate next to the nucleus as well as other smaller inclusions in
the cell. Note that addition of niclosamide alone may only cause
the degradation of a small portion of ubiquitinated proteins as the
proteasome is still active. This could potentially lead to a small
decrease of the amount of ubiquitin in the cell. Indeed,
niclosamide treatment alone mainly affects histone H2A ubiqui-
tination, which has been shown to be sensitive to proteotoxic stress
and lower amount of free ubiquitin [32,47]. In addition, because
lysosomes are redistributed, the clearance of the insoluble proteins
by the lysosome, accumulating next to the centrosome, may not be
as effective as in unstressed cells, and a small amount of
ubiquitinated proteins accumulates forming a small inclusion
(next to the nucleus).
Found at: doi:10.1371/journal.pone.0014410.s006 (0.15 MB TIF)
Movie S1 Live cell imaging of the formation of large ubiquitin-
containing aggregates during proteasome inhibition. SH-SY5Y
cells stably expressing GFP-ubiquitin were treated with 20 mM
MG132 and place in the pre-warmed Chamlide IC microscope
chamber supplied with 5% CO2. One hour later, imaging was
initiated and images were taken every 15 minutes. Selected time
points of this movie are shown in Fig. 1A.
Found at: doi:10.1371/journal.pone.0014410.s007 (2.06 MB
MOV)
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